Reviewing Axsome Therapeutics Inc. (AXSM)’s and Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s results

As Biotechnology businesses, Axsome Therapeutics Inc. (NASDAQ:AXSM) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics Inc. N/A 0.00 28.80M -1.13 0.00
Idera Pharmaceuticals Inc. N/A 113.48 59.88M -2.48 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Axsome Therapeutics Inc. and Idera Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics Inc. 0.00% -310.9% -113.7%
Idera Pharmaceuticals Inc. 0.00% -68.4% -60.4%

Liquidity

The Current Ratio of Axsome Therapeutics Inc. is 1.5 while its Quick Ratio stands at 1.5. The Current Ratio of rival Idera Pharmaceuticals Inc. is 8.2 and its Quick Ratio is has 8.2. Idera Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Axsome Therapeutics Inc.

Analyst Ratings

In next table is shown Axsome Therapeutics Inc. and Idera Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Axsome Therapeutics Inc. 0 0 0 0.00
Idera Pharmaceuticals Inc. 0 0 3 3.00

Meanwhile, Idera Pharmaceuticals Inc.’s consensus price target is $11.67, while its potential upside is 329.04%.

Insider and Institutional Ownership

Institutional investors held 12.9% of Axsome Therapeutics Inc. shares and 46.5% of Idera Pharmaceuticals Inc. shares. 30.4% are Axsome Therapeutics Inc.’s share held by insiders. On the other hand, insiders held about 0.7% of Idera Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axsome Therapeutics Inc. -12.24% -3.46% 154.72% 145.45% 217.65% 187.23%
Idera Pharmaceuticals Inc. -2.74% 12.25% -55.9% -71.46% -80.06% 2.53%

For the past year Axsome Therapeutics Inc. has stronger performance than Idera Pharmaceuticals Inc.

Summary

Idera Pharmaceuticals Inc. beats Axsome Therapeutics Inc. on 5 of the 8 factors.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.